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Abstract
Human IgG1 Fc has been widely used as a bioconjugate, but exhibits shortcomings, such as antibody- and comple-
ment-mediated cytotoxicity as well as decreased bioactivity, when applied to agonistic proteins. Here, we constructed a
nonimmunogenic, noncytolytic and flexible hybrid Fc (hyFc) consisting of IgD and IgG4, and tested its function using
erythropoietin (EPO) conjugate, EPO-hyFc. Despite low amino acid homology (20.5%) between IgD Fc and IgG4 Fc, EPO-
hyFc retained ‘‘Y-shaped’’ structure and repeated intravenous administrations of EPO-hyFc into monkeys did not generate
EPO-hyFc-specific antibody responses. Furthermore, EPO-hyFc could not bind to FccR I and C1q in contrast to EPO-IgG1 Fc.
In addition, EPO-hyFc exhibited better in vitro bioactivity and in vivo bioactivity in rats than EPO-IgG1 Fc, presumably due to
the high flexibility of IgD. Moreover, the mean serum half-life of EPO-hyFc(H), a high sialic acid content form of EPO-hyFc,
was approximately 2-fold longer than that of the heavily glycosylated EPO, darbepoetin alfa, in rats. More importantly,
subcutaneous injection of EPO-hyFc(H) not only induced a significantly greater elevation of serum hemoglobin levels than
darbepoetin alfa in both normal rats and cisplatin-induced anemic rats, but also displayed a delayed time to maximal serum
level and twice final area-under-the-curve (AUClast). Taken together, hyFc might be a more attractive Fc conjugate for
agonistic proteins/peptides than IgG1 Fc due to its capability to elongate their half-lives without inducing host effector
functions and hindering bioactivity of fused molecules. Additionally, a head-to-head comparison demonstrated that hyFc-
fusion strategy more effectively improved the in vivo bioactivity of EPO than the hyperglycosylation approach.
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Introduction
The application of Fc-fusion strategies to therapeutic proteins
has become increasingly popular in recent years, as evidenced by
the appearance of commercial products such as Orencia (CTLA-
4-Fc), Amevive (LFA3-Fc) and Enbrel (TNFR-Fc) [1]. Fusion with
an Fc fragment could extend the serum half-life of conjugated
therapeutics for two reasons: it is recycled via the neonatal Fc
receptor (FcRn) and creates a larger effective molecular size [2].
After internalization by fluid-phase pinocytosis, Fc-fusion proteins
bind to FcRn under the acidic pH conditions of endosomes and
are released at the basic pH level of blood, a pathway known to be
the main mechanism responsible for the long serum half-life of
IgG [3]. In addition, the larger hydrodynamic size of Fc-fusion
proteins inhibits their translocation from blood to extravascular
tissues and reduces their renal clearance [4].
Human IgG1 has been one of the most widely used human
immunoglobulin (Ig) Fc molecules, but it is inefficient in generating
long-acting agonistic proteins. This is largely because human IgG1
is able to bind to the Fcc receptor I (FccR I) or complement
component 1q (C1q), resulting in antibody-dependent cellular
cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC)
of target cells in vitro and in vivo [5]. Directed mutation or deletion of
FccR I or C1q binding sites has been employed in an attempt to
disrupt this binding and eliminate cytotoxicity [6]. However,
because these mutant residues must be exposed on the protein
exterior in order to disrupt binding to counterpart surfaces on the
cognate receptor, such mutagenesis strategies have led to concerns
that the mutated or deleted sequences might cause undesirable
immune responses. An alternative approach is to use IgG4 Fc,
which cannot bind FccR III or C1q [7]. However, IgG4 Fc still
retains moderate binding affinity for FccR I and its hinge region is
less flexible than that of IgG1 Fc. More problematically, it has been
reported that IgG4 Fc can form two intrachain disulfide bonds,
which can cause the generation of monovalent half-molecules [8].
Another strategy for circumventing the weaknesses of IgG1 is to
construct hybrid Fc molecules. On such hybrid molecules, IgG1/
IgG2 cannot bind to FccR I but is still able to bind to C1q [9].
Exploiting the fact that IgG2 does not bind to FccR I/III and IgG4
does not activate complement, two groups independently construct-
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hybrid IgG2/IgG4, substituting residues of the IgG2 backbone that
are important for C1q binding with the corresponding IgG4
residues. The IgG2 amino acids flanking these substitutions are
identical to those in the native IgG4 sequence; thus, the stretches of
amino acids with substitutions in IgG2 are also present in IgG4.
Another IgG2/IgG4 hybrid, eculizumab (Soliris), is a monoclonal
antibody against the terminal complement protein C5 consisting of
the hinge and CH1 regions of IgG2 and the CH2 and CH3 regions
of IgG4 [11]. In this hybrid, IgG2 and IgG4 were joined at a
restriction endonuclease site-containing oligonucleotide with flank-
ing sequences identical to those of IgG2 and IgG4. However,
without mutating or substituting sites, it is difficult to completely
avoid ADCC and CDC. In addition, this strategy imposes more
severe steric hindrance between neighboring molecules and
diminishes bioactivity due to the relatively low hinge flexibility of
IgG2 (32u).
Erythropoietin (EPO) is a naturally occurring, 30-kDa (165
amino acid) hematopoietic growth factor produced by the kidney
[12]. As the primary regulator of erythropoiesis, EPO stimulates
the proliferation of bone marrow erythroid precursor cells and
promotes their differentiation into red blood cells (RBCs) in
response to a decrease in tissue oxygenation [13]. However, the
terminal serum half-life (t1/2) of recombinant EPO (r-EPO) ranges
from 5 to 11 hours (hrs) after intravenous (IV) administration,
necessitating frequent administration [14]. It has been reported that
the increase in the RBC population in response to administration of
r-EPO is mainly regulated by the persistence of EPO exposure [15].
Thus, enhancing the duration of serum EPO could substantially
increase the dosing interval, potentially providing an important
therapeutic benefit. Two different strategies—hyperglycosylation
[16] and polyethylene glycol (PEG)-conjugation [17]—have been
developed to extend the serum half-life of EPO. One well-
established modified EPO, darbepoetin alfa (Aranesp, NESP), is a
heavily glycosylated EPO analogue that has been used for 10 years
to treat anemia. Unlike native EPO, which contains one O-linked
and three N-linked carbohydrate chains with a maximum of 14
sialic acids [18], darbepoetin alfa was engineered to include two
additional N-linked carbohydrate chains containing a maximum of
22 sialic acids [16]. Micera (C.E.R.A), another recently introduced
and commercially available modified EPO, is a pegylated form
made by linking the N-terminal amino lysine group of epoetin beta
with methoxy polyethylene glycol-succinimidyl butanoic acid
through amide bonds [17]. Both of these modified EPOs exhibit
reduced ability to bind the EPO receptor (EPOR) compared to r-
EPO; however, they exhibit greater in vivo biological activity as a
result of their longer serum half-lives [19,20]. These properties
permit less frequent dosing of patients while maintaining biological
effects.
In this study, we developed a novel type of hybrid Fc (hyFc),
which is nonimmunogenic and noncytolytic Fc having on intact
Ig structure, consisting of human IgD and IgG4 without any
additional artificial amino acids. In addition, EPO fused with hyFc
(EPO-hyFc) achieved better in vitro and in vivo bioactivity than
EPO-IgG1 Fc, possibly owing to the flexible hinge region. More
significantly, a head-to-head comparison with darbepoetin alfa,
which has been extensively used in clinic, showed that the hyFc-
fusion strategy more effectively improved recovery from cisplatin-
induced anemia as well as the in vivo bioactivity of EPO in normal
rats than did the hyperglycosylation approach, especially after
subcutaneous (SC) administration. Our findings suggest that hyFc
could be easily used for manufacturing a second generation of
other therapeutic proteins commercially available now, such as G-
CSF, human growth hormone and factor VII. More importantly,
hyFc could be applied to therapeutic short peptide such as GLP-1
(30 aa, t1/2 2 min [21]) and BNP (32 aa, t1/2 20 min [22]), which
have not been used in clinics due to very short half-lives in vivo.
Materials and Methods
Animals
Sprague-Dawley (SD) male rats at 6 to 8 weeks old were
purchased from Japan SLC. Rats are housed under specific
pathogen free (SPF) conditions in an approved animal facility at
Postech Biotech Center. Rat experiments were performed in
accordance with the procedures outlined in the guide for the care
and use of laboratory animals and approved by POSTECH
animal committee (2010-02-0003). Male and Female cynomolgus
monkeys at 2 to 3 years old were purchased from Guangxi
Grandforest scientific primate company (China) and were
acclimated for a 3-month period in Korea Institute of Toxicology.
Monkeys were also cared for in accordance with the guidelines
outlined in the guide for the care and use of laboratory animals
[23].
Construction of cell lines
The coding sequences for human EPO, the human IgG1 Fc
(hinge, CH2 and CH3 domains) that contains the same amino
acid sequences of Fc used for CTLA4Ig, and the hybrid Fc that
contains the 30 amino acids (aa) (133
th–162
nd) of the C-terminal
IgD hinge, the 8 aa (SHTQPLGV; 163
rd–170
th) of the N-terminal
IgD CH2 domain, the 100 aa (121
st–220
th) of the IgG4 CH2
domain, and the 107 aa (221
st–327
th) of the IgG4 CH3 domain
were obtained from codon-optimization synthesis (TOP Gene
Technologies, Montreal, Canada) (Fig. 1A). These were moved
into the pAD11 vector showing a 12-fold increase in expression
level compared with the RcCMV vector (Invitrogen, CA, USA)
(unpublished data). CHO/DHFR
2/2 cells (Chinese hamster
ovary cells, DG44, kindly provided by Dr. Chain of Columbia
University) were transfected with genes for EPO-IgG1 Fc and
EPO-hyFc according to the conventional CaPO4 coprecipitation
methods [24]. Transfected cells were selected for growth in the
presence of 0.18 mM methothrexate (Sigma-Aldrich, MO, USA)
and adapted in suspension culture using Ex-Cell CHO DHFR
2
animal-component free medium (SAFC, MO, USA).
Purification of EPO-hyFc and EPO-IgG1 Fc
For purification, HiTrap recombinant protein A FF columns
(Amersham Biosciences, NJ, USA) were equilibrated with phos-
phate-buffered saline (PBS) (pH 7.0). The filtered supernatants were
added to the columns and eluted with 0.1 M sodium citrate
(pH 3.0) followed by neutralization with 1 M Tris-HCl (pH 9.0).
Eluted samples were passed through an additional gel filtration
column (Superdex 200 and Acta Explorer; GE Healthcare, NJ,
USA) with 100 nMsodiumcitrate buffer(pH 4.0).Lessglycosylated
EPO-hyFc (EPO-hyFc(L)) was obtained from the flow-through after
loading onto a Q sephrose FF column (GE Healthcare, NJ, USA);
highly glycosylated EPO-hyFc (EPO-hyFc(H)) was also eluted with
10 mM sodium phosphate, 100 mM Arginine, 50 mM NaCl
(pH 6.9). The proteins were finally obtained after undergoing
dialysis with a membrane (MWCO 12–14K; Spectrum, CA, USA)
more than three times.
Small X-ray scattering (SAXS)
SAXS experiments were performed at the beamline 4C1 of the
Pohang Light Source as previously described [25]. The low
resolution structure of EPO-hyFc was reconstituted by using an ab
initio shape-determination program, GASBOR [26]. The struc-
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Inc.) on the basis of two structures of EPO (1BUY) and IgG
(3DNK).
FccR I- and C1q-binding assays
The FccR I- and C1q-binding activity of EPO-hyFc was
determined by FccR I and C1q ELISA as described [10] with
minor modification. EPO-hyFc, EPO-IgG1 Fc, Herceptin (Roche,
Basel, Switzerland) and Enbrel (Amgen, CA, USA) with 2-fold or
3-fold serial dilution (starting concentration: 2 mg/ml for FccRIo r
100 mg/ml for C1q) in PBS were coated in 96-well immunoplates
(Nunc, Copenhagen, Denmark) and left overnight at 4uC. After
blocking, 100 mlo f2mg/ml human FccR I (R&D, MN, USA) or
human C1q (AbD SEROTEC, NC, USA) was added. Next,
sequential treatment of 2 mg/ml biotin-conjugated anti-human
IgG1 antibody (R&D, MN, USA) and 1:3000-diluted streptavidin-
HRP (BD Bioscience, CA, USA) or treatment of 1:400-diluted
HRP-conjugated anti-C1q antibody (AbD SEROTEC, NC, USA)
was performed. After washing, 50 ml TMB substrate (KPL, MD,
USA) was added; the reaction was stopped by the addition of 50 ml
2NH 2SO4. The optical density (OD) was determined at 450 nm
after subtracting the OD at 590 nm.
In vitro bioassay of EPO derivatives
In vitro bioassay of EPO derivatives was carried out as described
[27] with minor modification. The human leukemic F36E cells
(RIKEN BRC, Japan) were maintained with 5 IU/ml darbepoetin
alfa (Aranesp; Amgen, CA, USA) in assay media. After 1 day of
darbepoetin alfa starvation, starved F36E cells were resuspended
at 1610
5 cells/ml and a total of 100 ml( 1 610
4 cells) of the cell
suspension was aliquoted to each test well. Serial 2-fold dilutions of
r-EPO (batch 3; EDQM, Strasbourg, France), darbepoetin alfa,
EPO-hyFc and EPO-IgG1 Fc were also prepared in assay media.
A total of 100 ml of the diluted EPO derivatives were added to the
triplicate wells. After 3 days, 20 ml of CellTiter 96 Aqueous One
Solution (Promega, WI, USA) was added to each well and the
plates were incubated at 37uC in the tissue culture incubator for
4 hrs. Absorbance of the wells was read at 490 nm using a
microplate reader.
Colony assays
Methocult media M3234 (Stem Cell Technologies, BC, USA)
was used for colony assays according to the manufacturer’s
instructions with minor modification. Bone marrow cells isolated
from 6-week-old C57bl/6 mice were suspended in Iscove’s
Figure 1. Schematic diagram of EPO-IgG1 Fc and EPO-hyFc, and X-ray structure of EPO-hyFc. (A) Schematic diagram of hyFc and IgG1 Fc
fused with EPO. The numbers in the boxes denote the amino acid numbers from the CH1 region of each immunoglobulin. (B) The structure of EPO-
hyFc, determined by small-angle X-ray scattering, was reconstituted from the known structure of EPO. The sheets in the structure were fit based on
the crystal structure.
doi:10.1371/journal.pone.0024574.g001
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serum (FBS) and loaded onto 35 mm non-adhesive culture dishes
(1610
5 cells/ml/dish; Stem Cell Technologies, BC, USA) with
1 nM of r-EPO, darbepoetin alfa, EPO-hyFc, or EPO-IgG1 Fc.
All samples were cultured in a humidified incubator at 37uC with
5% CO2. The colonies were counted directly using an inverted
microscope on day 2 for erythroid colony-forming unit colonies
(CFU-E) and on day 8 for erythroid burst-forming unit colonies
(BFU-E).
Pharmacokinetic study in rats
To compare the half-life of EPO-hyFc and EPO-IgG1 Fc, six
SD male rats were treated with a single IV injection of 400-pmol/
kg r-EPO, EPO-hyFc and EPO-IgG1 Fc. After IV injection, blood
samples were drawn before injection and at timepoints up to
168 hpi (hours post injection).
To examine comparative pharmacokinetic profiles of darbe-
poetin alfa and EPO-hyFc(H), groups of ten SD male rats were
injected intravenously or subcutaneously with 800-pmol/kg
darbepoetin alfa and EPO-hyFc(H). After IV and SC administra-
tion, blood samples were drawn from 5 rats each at alternative
time points before injection and at timepoints up to 168 hpi. Sera
from each sample were stored in a 280uC freezer. All samples
obtained at each time point were tested for the quantification of
EPO by EPO ELISA kit (R&D, MN, USA) according to the
manufacturer’s protocol.
Pharmacodynamic study in rats
After a single IV administration of 400-pmol/kg r-EPO, EPO-
IgG1 Fc, EPO-hyFc and buffer into six male SD rats, blood
samples were collected daily up to 8 days post injection (dpi) in a
K3 EDTA vacutainer tube (BD Bioscience, CA, USA) to inhibit
coagulation. One milliliter of Retic-COUNT
TM solution (thialzole
orange; BD Bioscience, CA, USA) was aliquoted into polystyrene
tubes (12675 mm) and 5 ml of each blood sample was added.
After incubation at room temperature for 30 min under dark
conditions, the number of reticulocytes in these samples was
measured by FACS Calibur (BD Bioscience, CA, USA).
A dose of 135-pmol/kg darbepoetin alfa and EPO-hyFc(H) as
well as buffer was administrated into five SD male rats via IV and
SC routes. For establishing the chemical-induced anemic models,
6 mg/kg of cisplatin (Joongwea Pharmaceuticals, Korea) was
treated via intraperitoneal route into SD male rats. Nine days after
cisplatin treatment, 100-pmol/kg darbepoetin alfa and EPO-
hyFc(H) were administered via IV (n=8) and SC (n=6) routes.
Blood samples were drawn before injection and at timepoints up to
27 dpi and collected in a K3 EDTA vacutainer tube. Hemoglobin
(Hb) level was determined using an automated CBC counter
(MELET SCHLOESING Lab., France).
Immunological and hematological responses by
EPO-hyFc(H) treatment in monkeys
Cynomolgus male and female monkeys were treated with 1, 3,
10 mg/kg of EPO-hyFc(H) or vehicle control twice a week for four
weeks (9 times; from day 1 to 29) via IV route (n=10, buffer
control and 10 mg/kg-treated groups; n=6, 1 and 3 mg/kg-treated
groups). Anti-EPO-hyFc specific antibody responses were deter-
mined at day 15, 29 (n=6 or 10 in all groups), 44, 58 and 72 (n=4
in vehicle control or 10 mg/kg-treated group) by ELISA as
described [28,29]. EPO-hyFc(H) was diluted to 1 mg/ml in PBS
and coated in 96-well immunoplates (Nunc, Copenhagen, Den-
mark). After blocking, 100 ml of monkey sera or chicken polyclonal
anti-EPO antibody (Abcam, SF, USA) as a positive control was
added, followed by sequential treatment of 100 ml of biotin-
conjugated secondary antibody and 1:3000-diluted streptavidin-
HRP (BD Bioscience, CA, USA). After washing, 100 ml TMB
substrate (KPL, MD, USA) was added and the reaction was
stopped by the addition of 100 ml2 NH 2SO4. Normalized
negative cut off was determined by using monkey blank sera and
monkey sample sera showing higher optical density at 450 nm
than the negative cut off were re-tested by an immunodepletion
test, which examines the difference in the OD between before and
after reacting monkey sera with 1 mg/ml of EPO-hyFc(H). When
the difference in the OD was more than 30%, the sample was
regarded as positive. Before the administration (day 0) and one day
after the last administration (day 30), Hb concentration, RBC
counts and hematocrits were determined by ADVIA120 Hema-
tology System (Bayer, NY, USA).
Data and Statistical analysis
PK parameters were determined using a non-compartmental
approach using WinNonlin (Pharsight Corp., CA, USA) including
terminal half-life (t1/2), area under the curve-last (AUClast, from
time zero to the time of the last quantifiable concentration),
maximum serum concentration (Cmax), initial serum concentration
(C0) and time to Cmax (Tmax). All values are expressed as the mean
6 the standard error of the mean (SEM). A two-tailed student’s t-
test was used to examine statistical differences between the
experimental groups.
Results
Characteristics of recombinant EPO-hyFc
Recombinant EPO-hyFc and EPO-IgG1 Fc (Fig. 1A) were
produced from CHO cell lines and purified (.99% pure) from
serum-free culture media by protein affinity chromatography and
size exclusion chromatography as described in ‘‘Material and
methods’’. As expected, the purified EPO-hyFc protein consisted of
a homodimer of approximately 130 kDa, which is slightly heavier
than the EPO-IgG1 Fc protein (approximately 110 kDa) (Fig. S1);
both proteins had similar pI values, indicating comparable
carbohydrate content (data not shown). In contrast to the greater
than 95% homology observed among other IgG subclasses, the
amino acid homology between IgD Fc and IgG4 Fc is only 20.5%.
Despite this low sequence homology, the ‘‘Y-shaped’’ structure of
hyFc was confirmed by small X-ray scattering, indicating that the
hyFc consisting of IgD Fc and IgG4 Fc retained an intact Ig-like
structure (Fig. 1B).
Because hyFc contains the upper CH2 domain of IgD and the
last CH2 and CH3 domains of IgG4, which do not have FccR- or
C1q-binding sites, we examined the binding affinity of EPO-hyFc
to recombinant FccR I and C1q proteins. Using ELISA, we found
that EPO-hyFc was unable to bind either protein over a
concentration range of 31.2 to 2000 ng/ml for FccR I and 0.1
to 100 ug/ml for C1q (Fig. 2). In contrast, EPO-IgG1 Fc,
Herceptin, and Enbrel used as positive controls bound both FccR
I and C1q. Additionally, when monkeys received 10 mg/kg of
EPO-hyFc(H) 9 times via IV routes, there was mild and moderate
bone marrow hyperplasia, which might be associated with
erythropoiesis. However, no destructive feature was found in
bone marrow where in vivo erythropoiesis occurs (Fig. S2),
suggesting that hyFc would not induce antibody-mediated
cytotoxicity.
Improved bioactivity of EPO-hyFc over EPO-IgG1 Fc
To compare the in vitro bioactivity of EPO-hyFc and EPO-IgG1
Fc, we first evaluated the proliferation of EPO-responsive human
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EPO proteins. r-EPO and darbepoetin alfa were used as controls.
As expected, all EPO forms induced a concentration-dependent
increase in cell number, as evidenced by the shape of the
proliferation curve (Fig. 3A). The half-maximal effective dose of
EPO-hyFc (ED50, 27.6 pM) was the lowest, whereas that of EPO-
IgG1 Fc (111.5 pM) was the highest (Fig. 3B). Consistent with a
previous report [16], the in vitro bioactivity of darbepoetin alfa was
lower (i.e., higher ED50, 84.4 pM) than r-EPO (52.9 pM) due to its
high sialic acid content. Considering that one EPO-hyFc molecule
contains two EPO molecules, ED50 of an individual EPO is
55.2 pM, which is comparable to that of r-EPO, indicating that
there was no significant loss of bioactivity of EPO by hyFc-fusion.
Also, colony formation assays were performed to determine the
effect of EPO-hyFc on the proliferation of bone marrow erythroid
progenitor cells by quantifying CFU-Es (late erythroid progenitors)
and BFU-Es (early erythroid progenitors). One micromole of r-
EPO and darbepoetin alfa treatment resulted in 131.8 and 105.3
CFU-E colonies, respectively (Fig. 3C). EPO-hyFc led to the
highest number of CFU-E colonies (159.0), which is higher than
those by EPO-IgG1 Fc treatment (123.5). Consistently, r-EPO and
EPO-IgG1 Fc treatment induced comparable BFU-E colonies
(15.0 and 14.7). In contrast, darbepoetin alfa and EPO-hyFc
treatment generated the lowest (7.5) and the highest (22.7)
numbers of BFU-E colonies, respectively. Taken together, these
results suggest that EPO-hyFc is more effective in generating both
CFU-E and BFU-E than EPO-IgG1 Fc, indicating the importance
of a flexible hinge region.
To compare the pharmacokinetic profiles of the two Fc-fused
EPO proteins, we delivered a single 400-pmol/kg dose of r-EPO,
EPO-hyFc, or EPO-IgG1 Fc into SD rats via the IV route. The
serum half-life of r-EPO, used as a control, was 5.5 hours (Table 1,
Fig. 4A), consistent with previous reports [14]. Notably, both
EPO-IgG1 Fc and EPO-hyFc were cleared about five-times more
slowly than r-EPO; moreover, the serum half-life of EPO-hyFc
(29.1 hours) was longer than that of EPO-IgG1 Fc (24.7 hours).
Additionally, the AUClast (area under the concentration-time
curve up to the last quantifiable concentration) values for EPO-
IgG1 Fc and EPO-hyFc were about 9- and 10-fold larger than that
for r-EPO, indicating that the fusion of either hyFc or IgG1 Fc
increased the in vivo residence time of EPO.
Concomitant with the pharmacokinetic study, the percentage of
reticulocytes in blood, a marker of in vivo bioactivity of EPO, was
measured daily by flow cytometry. As shown in Fig. 4B and 4C,
the number of reticulocytes in EPO-IgG1 Fc-injected rats was
increased at 4 and 5 dpi compared to r-EPO-injected rats, peaking
at 4 dpi (relative increase of 9.35%). In contrast, EPO-hyFc
significantly increased reticulocyte numbers from 2 to 5 dpi to an
even greater extent (relative increase of 13.27%; peak at 4 dpi,
p,0.01). PBS-treated group has a tendency to slightly increase
reticulocytes, presumably due to the frequent bleeding for PK
study, which is consistent with a previous report [30]. The AUClast
for the increase in reticulocytes generated by EPO-hyFc reached
29.8 d6%, which was approximately 2.3- and 1.7-fold higher
than that generated by r-EPO (13.0 d6%) and EPO-IgG1 Fc
(17.5 d6%), respectively. Taken together, our results indicate that
the flexibility of the hyFc-hinge region may be mainly responsible
for the better in vivo bioactivity of EPO-hyFc compared to EPO-
IgG1 Fc.
Differences in the pharmacokinetic and
pharmacodynamic profiles of EPO-hyFc and darbepoetin
alfa in rats
Because sialic acid content plays a role in the in vivo half-life of
proteins, as shown in darbepoetin alfa, we separated purified
EPO-hyFc into high and low sialic acid forms by Q sepharose
chromatography. The high sialic acid form, EPO-hyFc(H),
contained approximately 26 sialic acid residues/molecule, and
the low sialic acid form, EPO-hyFc(L), contained about 16 sialic
acids/molecule. An isoelectric focusing (IEF) analysis showed that
the pI values for EPO-hyFc(H) and EPO-hyFc(L) were 4.4–5.0
and 5.1–6.6 pI, respectively (data not shown). As expected, EPO-
hyFc(H) showed significantly enhanced in vivo bioactivity com-
pared to EPO-hyFc(L) in BDF-1 mice after SC administration
(Fig. S3). Consistent with this, we also found that EPO-hyFc(H)
had a longer serum half-life and significantly higher C0 (initial
observed serum concentration) than EPO-hyFc(L) (data not
shown). These findings are also in agreement with a previous
report that IgG2a Fc-EPO fusion molecules with higher sialic acid
content isolated from BHK cells showed improved in vivo
pharmacokinetic and pharmacodynamic profiles compared with
those with lower sialic acid content isolated from NS/0 and 293
cells [31].
Next, since darbepoetin alfa has been considered the gold
standard for a long-acting, second-generation of EPO analogue,
which has been extensively used in clinics, we performed a head-
to-head comparison of the pharmacokinetic profiles of EPO-
hyFc(H) and darbepoetin alfa (Table 2, Fig. 5A). The half-life
of IV-administered EPO-hyFc(H) was significantly increased
compared to darbepoetin alfa (25.3 vs. 13.8 hours, p,0.01);
Figure 2. Binding capability of EPO-hyFc to FccR I and C1q. Binding of EPO-hyFc (N), EPO-IgG1 Fc (#), Enbrel (]), and Rituxan (%) to human
FccR I (A) and human C1q (B) was assessed by an indirect ELISA method. Data, presented as means 6 SEMs, are obtained from three independent
experiments.
doi:10.1371/journal.pone.0024574.g002
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24574although the AUClast for EPO-hyFc(H) trended higher (233.3 vs.
205.2 h?pmol/ml), this difference did not reach statistical signi-
ficance. Unexpectedly, the C0 for EPO-hyFc(H) was less than that
for darbepoetin alfa (11.2 vs. 18.6 pmol/ml, p,0.01), which may
account for the lack of a significant difference in their AUClast
values despite the longer half-life of EPO-hyFc(H). EPO-hyFc(H)
administered via the SC route exhibited a similar increase in
serum half-life (31.6 vs. 15.6 hours, p,0.01), and also achieved a
significantly higher AUClast than darbepoetin alfa (138.1 vs.
92.2 h?pmol/ml, p,0.01). Although Cmax (maximum observed
serum concentration) of EPO-hyFc(H) was slightly lower than that
of darbepoetin alfa (2.09 vs. 2.51 pmol/ml), the Tmax (time of
Cmax) of EPO-hyFc(H) was significantly delayed compared to
darbepoetin alfa (30.8 vs. 17.6 hours, p,0.05). These results
suggest that hyFc fusion mediates a longer duration of above-
threshold EPO levels in blood. The relative bioavailability of
EPO-hyFc(H), determined as the AUClast after SC administration
relative to the mean AUClast after IV administration, was
also significantly higher than that of darbepoetin alfa (59.2%
vs. 44.9%, p,0.01), indicating that EPO-hyFc(H) is efficiently
absorbed and utilized compared to darbepoetin alfa, especially
following SC administration.
To compare the effects of EPO-hyFc(H) and darbepoetin alfa
on in vivo erythropoiesis, we evaluated the profiles of serum Hb
concentration versus time in rats after administering the same
molar amounts of darbepoetin alfa or EPO-hyFc(H) via IV and
SC routes (Fig. 5B). EPO-hyFc(H) administration led to a signi-
ficantly higher Hb concentration than darbepoetin alfa at 14 dpi
Figure 3. In vitro bioactivity of r-EPO, darbepoetin alfa, EPO-hyFc and EPO-IgG1 Fc. In vitro bioactivity of r-EPO (m), darbepoetin alfa (g),
EPO-hyFc (N), and EPO-IgG1 Fc (#) was determined by their effect on F36E cell proliferation shown as concentration dependence (in molar terms) (A)
and ED50 (B) and on the number of CFU-Es and BFU-Es generated from bone marrow progenitor cells of C57bl/6 mice (C). Data, presented as means
6 SEMs, are derived from four (F36E proliferation) and three (colony assays) independent experiments. (*p,0.05, **p,0.01)
doi:10.1371/journal.pone.0024574.g003
Table 1. Pharmacokinetic parameters of r-EPO, EPO-hyFc and
EPO-IgG1 Fc after IV administration into rats.
Dose,
pmol/kg
AUClast
a,
hr6pmol/ml
C0
b,
pmol/ml
t1/2
c,
hr
r-EPO 400 13.660.4 3.660.2 5.560.2
EPO-hyFc 400 139.564.2 9.060.5 29.161.3
EPO-IgG1 Fc 400 127.663.3 7.760.3 24.760.4
aarea under the concentration-time curve up to the last quantifiable
concentration.
binitial observed serum concentration at 5 min.
cterminal serum half-life.
doi:10.1371/journal.pone.0024574.t001
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24574Figure 4. Pharmacokinetic and pharmacodynamic profiles of r-EPO, EPO-hyFc, and EPO-IgG1 Fc in rats. A single 400 pmol/kg dose of
r-EPO(m),EPO-hyFc(N), orEPO-IgG1Fc(#) was administeredinSDrats (n=6/group), (A)serumEPOlevelsversustimewere determinedattheindicated
timepointsbyEPOELISA.(B,C)Absolutereticulocytecounts(B)andchangesinreticulocytecounts(C)inblood,expressedrelativetothelevelsinbuffer-
treated rats after excluding the level determined prior to the administration, were evaluated by flow cytometry. Data, presented as means 6 SEMs, were
obtained from a single experiment. (*p,0.05, **p,0.01 compared with r-EPO; {p,0.05, {{p,0.01 compared with EPO-IgG1 Fc).
doi:10.1371/journal.pone.0024574.g004
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administration of EPO-hyFc(H) trended higher than that after IV
administration of darbepoetin alfa, as did the AUClast of the Hb
increase (47.2 vs. 39.2 d?g/dL), although these differences were
statistically insignificant. In contrast, SC administration of EPO-
hyFc(H) induced a significantly greater Hb concentrations than
did darbepoetin alfa at 10 and 14 dpi and significantly augmented
the AUClast of Hb increase compared to darbepoetin alfa (45.0 vs.
24.4 d?g/dL, p,0.01). Interestingly, EPO-hyFc(H) exhibited an in
vivo bioactivity comparable to that of darbepoetin alfa even at a
molar amount one-third that of darbepoetin alfa (Fig. S4). These
results imply that, even considering that one EPO-hyFc molecule
contains two EPO molecules, EPO-hyFc(H) is superior to
darbepoetin alfa in terms of increased Hb levels, especially when
administered via the SC route. To investigate in vivo erythropoiesis
by darbepoetin alfa and EPO-hyFc(H) in cisplatin-induced anemic
rats, rats were treated with 6 mg/kg cisplatin via intraperitoneal
route, leading to decreased Hb concentration up to around 12 g/
dL showing mild anemia. The mean Hb concentrations achieved
by EPO-hyFc(H) administration via IV route appeared to be
higher at 10 to 28 dpi than those by darbepoetin alfa, as did the
AUClast of the Hb increase (58.0 vs. 47.3 d?g/dL). More
significantly, SC administration of EPO-hyFc(H) augmented Hb
concentration from 14 to 28 dpi and AUClast of Hb increase
compared to darbepoetin alfa treatment (105.6 vs. 64.1 d?g/dL,
p,0.01), which is consistent with the results obtained from normal
rats, suggesting the possibility of delayed injection of EPO-hyFc(H)
compared to darbepoetin alfa. Additionally, we confirmed that the
increase in Hb levels and its duration by EPO-hyFc(H) after the
induction of more severe anemia were comparable to that in mild
anemic rats (Fig. S5). An increase in red blood cell counts and
hematocrit by darbepoetin alfa and EPO-hyFc(H) in both normal
and anemic rats showed a similar pattern with an increase in Hb
concentration (Fig. S6). Taken together, these results indicate that
EPO-hyFc(H) is highly effective in restoration from acute renal
failure through active erythropoiesis.
To examine the immunogenicity of EPO-hyFc(H) in cynomol-
gus monkeys, EPO-hyFc(H) was administered 9 times in three
different doses (1, 3, and 10 mg/kg) via IV route. When EPO-
hyFc(H)-specific antibody responses were determined by ELISA,
there was no antibody induction specific to EPO-hyFc(H) in sera
(Table 3), indicating that EPO-hyFc(H) would not be immuno-
genic. Additionally, there was no significant difference in the PK
profiles of EPO-hyFc(H) administrated between at day 29 and at
day 0, supporting the absence of EPO-hyFc-specific antibody
induction (Fig. 6A). When we determined the effect of EPO-
hyFc(H) on hematological responses, EPO-hyFc(H) treatment
increased Hb concentrations, RBC counts and hematocrits in a
dose-dependent manner (Fig. 6B).
Discussion
Human IgG1 Fc has been widely used in Fc-fusion strategies
for developing long-acting antagonistic proteins, such as TNFR
and CTLA-4, and provides a long half-life and improved
efficacy [1]. However, its effector functions, including ADCC
and CDC, would be disadvantageous when applied to agonistic
proteins as this would lead to the death of target cells. A simple
approach for overcoming this shortcoming is to directly mutate
or delete sites related to ADCC and CDC [6]; but this comes at
the cost of potential immunogenicity. Other methods include
utilization of IgG4 Fc [7] or hybrid IgG2/IgG4 Fc [10,11], but
these could form monomeric molecules and/or hinder the
bioactivity of Fc-fused molecules due to their less flexible hinge.
More seriously, any hybrid Ig between IgG subclasses could not
eliminate both ADCC and CDC completely. To circumvent
these obstacles, we constructed a natural form of highly flexible
hybrid Fc, hyFc, by replacing the hinge and the upper N-
terminal CH2 domains of IgG4 Fc (which are essential for
binding to all three human FccRs) with the corresponding
regions of IgD, a different class of Ig. Importantly, among
human Igs, IgD shows the highest hinge-fold flexibility (77u)
[32]. However, we previously found that the upper hinge region
of IgD containing O-glycan moieties severely inhibited in vivo
utilization after SC administration (unpublished data). We
therefore used a partial hinge of IgD, which still contains
considerable hinge-fold flexibility (53u) [32] compared to that of
IgG1 (43u)a n dI g G 2( 3 2 u) [33], to construct hyFc.
Despite the low sequence homology (20.5%) between IgG4 Fc
and IgD Fc, IgD exhibits a hydrophobicity profile similar to that of
IgG4, especially in the upper CH2 region (Fig. S7). On the basis of
a previous study that mutations do not disrupt Ig-like structure
as long as the properties of amino acids in the hydrophobic/
hydrophilic signature are conserved [34], we created a junction
site between IgD and IgG4 in the hydrophobic region of the upper
CH2 domain (Fig. S7) to maintain an intact hydrophobicity profile
as well as to locate the junction site at inner space of hyFc. As
expected, small X-ray scattering revealed that EPO-hyFc
exhibited the ‘‘Y-shaped’’ structure like other Igs (Fig. 1B), and
EPO-hyFc-specific antibody responses were not generated in
monkeys intravenously injected 9 times (Table 3).
It has been previously reported that as the number of N-linked
carbohydrates, especially terminal sialic acids, on EPO increased,
receptor-binding activity decreased [35]. In addition, there was a
Table 2. PK parameters of darbepoetin alfa and EPO-hyFc(H) after IV and SC administration into rats.
Route Dose, pmol/kg AUClast
a,h r 6pmol/ml Cmax
b, pmol/ml C0
c, pmol/ml Tmax
d,h r t 1/2
e,h r
Darbepoetin alfa IV 800 205.263.9 NA 18.660.4 N/A 13.860.5
EPO-hyFc(H) IV 800 233.362.2 NA 11.260.2 N/A 25.361.6
Darbepoetin alfa SC 800 92.260.5 2.5160.04 NA 17.661.8 15.661.0
EPO-hyFc(H) SC 800 138.164.6 2.0960.08 NA 30.863.5 31.661.6
NA ; not available.
aarea under the concentration-time curve up to the last quantifiable concentration.
bmaximum observed serum concentration.
cinitial observed serum concentration at 5 min.
dtime of maximum observed serum concentration.
eterminal serum half-life.
doi:10.1371/journal.pone.0024574.t002
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bioactivity and was the reason why darbepoetin alfa achieved less
bioactivity than r-EPO in vitro. Here, EPO-hyFc showed similar in
vitro bioactivity in the proliferation of F36E cells and erythroid
progenitors compared to r-EPO, which might be due to the
comparable sialic acid contents on EPO because any modification
was not introduced on it. In contrast, EPO-IgG1 Fc exhibited less
in vitro bioactivity than r-EPO and EPO-hyFc despite comparable
sialic acid contents on EPO, reflecting the inhibitory effect of steric
hindrance derived from IgG1 Fc.
Figure 5. Pharmacokinetic and pharmacodynamic profiles of EPO-hyFc(H) and darbepoetin alfa in rats. (A) Serum EPO levels versus
time after a single 800-pmol/kg dose of darbepoetin alfa (g) or EPO-hyFc(H) (N) administered IV or SC into SD rats (n=10/group) were determined at
the indicated time points (blood was collected from five rats each at alternate time points) by EPO ELISA. (B, C) The mean Hb concentrations versus
time after the administration of darbepoetin alfa (g) or EPO-hyFc(H) (N) into normal SD rats (n=5/group; 135-pmol/kg) (B) and cisplatin-induced
anemic rats (n=8 (IV) or 6 (SC) / group; 100-pmol/kg) (C) were evaluated at the indicated time points using an automated CBC counter. Changes in
Hb concentration were expressed relative to the levels in buffer-treated rats after excluding the level determined prior to administration. Data,
expressed as means 6 SEMs, are representative of those obtained from two experiments. (*p,0.05, **p,0.01 compared with darbepoetin alfa).
doi:10.1371/journal.pone.0024574.g005
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the serum half-life of therapeutic proteins such as EPO. The first
is receptor-mediated endocytosis and subsequent intracellular
degradation; EPO is degraded only by EPOR-expressing cells,
which include erythroid progenitor cells and non-hematopoietic
cells such as neurons, glia, myoblasts, and endothelial cells [36].
To date, the identity of cells that are mainly involved in EPOR-
mediated clearance has not yet been clearly established. The
second mechanism is rapid elimination of desialylated EPO via
an asialoglycoprotein receptor (ASGR) expressed on hepatocytes.
Consistent with this possibility, there is a positive correla-
tion between the number of sialic acids on EPO molecules and
serum half-life [35]. Last is hydrodynamic size-dependent renal
clearance: as the molecular size increases, the clearance in kidney
is decreased [4]. In contrast to darbepoetin alfa, which is able to
sustain a relatively long in vivo half-life due to its greater sialic acid
content (22 vs. 14 residues) and a larger molecular size (37.4 vs.
30 kDa) compared to EPO [16], additional mechanisms may
account for the longer serum half-life of EPO-hyFc. Although the
larger hydrodynamic size of EPO-hyFc (130 kDa) compared to
darbepoetin alfa (37.4 kDa) may contribute, FcRn-mediated
recycling may play a major role in the longer serum half-life of
EPO-hyFc, as evidenced by the significantly shorter serum half-
life of EPO-hyFc in FcRn-deficient mice than in wild-type mice
(data not shown). Unexpectedly, we found that the initial serum
levels of EPO-hyFc(H) were significantly lower than those of
darbepoetin alfa after IV injection, even though the larger
hydrodynamic size of EPO-hyFc is predicted to inhibit renal
clearance and extravasation. One explanation for this phenom-
enon is that EPO-hyFc may be internalized via FcRn into
endothelial cells and hematopoietic cells soon after IV injection
and is thus sequestered from blood. Alternatively, EPO-hyFc(H)
may be cleared via ASGRs in the liver owing to the fact that its
moieties are more asialylated than those of darbepoetin alfa
(8,11 vs. 0,4 residues [37]). Previous studies showing that
ASGR-mediated endocytosis and clearance occurs in a matter of
minutes [38] suggest that the latter explanation may be more
plausible. Additional support for this interpretation is provided by
our observation that the C0 of EPO-hyFc(L) is significantly lower
than that of EPO-hyFc(H).
It was reported that EPO-mimicking human antibody interacts
with different sites on EPOR compared to an EPO molecule, but
mediate the proliferation of EPO-responsive F36E cells and
increase hematocrits after administration [27]. In terms of
pharmacokinetics, EPO-mimicking antibody has a serum half-
life of approximately 6 days, which is a significantly longer than
darbepoetin alfa and EPO-hyFc(H). In contrast, EPO-mimicking
antibody showed 10-fold lower in vitro bioactivity than r-EPO,
while EPO-hyFc exhibited better activity than r-EPO on an
equivalent molar basis. In addition, although EPO-mimicking
antibody achieved better in vivo bioactivity than darbepoetin alfa,
leading to less frequent injections, approximately 80-fold more
EPO-mimicking antibody on a mass concentration was used. In
contrast, an equivalent mole of EPO-hyFc(H), which is about 3-
fold more on a mass concentration, induced better in vivo
bioactivity than darbepoetin alfa in rats, suggesting that EPO-
hyFc has an advantage in increasing bioactivity compared to
EPO-mimicking antibody. However, it is to early to conclude
relative effect in bioactivity due to the differences in experimental
scheme. Therefore, it would be interesting to perform a head-to-
head comparison between EPO-mimicking antibody and EPO-
hyFc.
It has been reported that EPO mediates the dimerization of
EPOR via asymmetric binding, followed by the activation of a
signaling pathway [39]. Two adjacent EPO molecules by short
linkers (3 to 7 aa) led to a moderate decrease in in vitro bioactivity
of EPO-EPO fusion molecules compared to EPO monomers [40].
In contrast, the usage of 17 aa linker for EPO-EPO induced
6-fold higher bioactivity than the monomer, although the exact
mechanisms have not yet been elucidated [41]. Similarly, we
found that one EPO-hyFc molecule having a 30 aa flexible hinge
region showed about 2-fold higher in vitro bioactivity than r-EPO,
suggesting no inhibitory effect of hyFc-fusion in the dimerization
of EPOR by each EPO molecule.
The bioavailability of r-EPO and darbepoetin alfa following
SC administration increased in a dose-dependent manner [42].
Therefore, head-to-head comparisons of the bioavailability using
molar-equivalent amounts of darbepoetin alfa and EPO-hyFc(H)
were important in providing information regarding the suitability
of SC administration. Interestingly, EPO-hyFc(H) exhibited
significantly higher bioavailability than darbepoetin alfa (59.2%
vs. 44.9%, p,0.01) after SC administration in rats. Previous
reports have suggested that there is a negative correlation
between hydrodynamic size and bioavailability [43,44]. In
addition, it has been reported that a high positive charge causes
nonspecific adhesion of proteins to the extracellular matrix and
inhibits their transport into the blood [45]. Despite the larger
hydrodynamic size and higher pI values of EPO-hyFc(H) than
darbepoetin alfa, which would be presumed to impede absorption
after SC administration compared to darbepoetin alfa, the
bioavailability of EPO-hyFc(H) was enhanced, possibly reflecting
FcRn-mediated internalization. A previous report demonstrated
that the bioavailability of monoclonal IgG1 antibody was
significantly decreased in FcRn-deficient mice compared to that
in wild-type mice (28.3% vs. 82.5% in FcRn-deficient vs. wild-
type mice, respectively) [46]. In addition, it has been shown that
Table 3. Induction of anti-EPO-hyFc antibody in cynomolgus monkeys.
during treatment
a after treatment
day 1 day 15 day 29 Day 44 day 58 day 72
G1 (vehicle control) 0/10
b 0/10 0/10 0/4 0/4 0/4
G2 (1 mg/kg EPO-hyFc(H)) 0/6 0/6 0/6 N/A N/A N/A
G3 (3 mg/kg EPO-hyFc(H)) 0/6 0/6 0/6 N/A N/A N/A
G4 (10 mg/kg EPO-hyFc(H)) 0/10 0/10 0/10 0/4 0/4 0/4
NA ; not applicable.
aNine times administration of EPO-hyFc(H) twice a week.
bNumber of true positive animals/number of animals tested.
doi:10.1371/journal.pone.0024574.t003
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arterioles and capillaries, and that FcRn-binding proteins are
predominantly localized in skin and muscle and, to a lesser
extent, in liver and adipose tissue [47]. It is not yet known
whether the effect of FcRn on SC bioavailability is mainly
associated with FcRn-mediated protection from degradation
or FcRn-mediated transport from the interstitial fluid to the
blood through the vascular endothelium. However, the former
mechanism is more conceivable because EPO-hyFc(H) showed a
delayed Tmax compared to darbepoetin alfa.
Figure 6. Pharmacokinetic and pharmacodynamic profiles of EPO-hyFc(H) in monkeys. (A) Serum EPO levels versus time after the first
(day 1) and ninth (day 29) IV administration of 1, 3, and 10 mg/kg dose of EPO-hyFc(H) into cynomolgus monkeys (n=10, buffer control and 10 mg/kg-
treated groups; n=6, 1 and 3 mg/kg-treated groups) were determined at the indicated time points by EPO ELISA. (B) The mean Hb concentrations,
RBC counts and hematocrits before (day -4) or after nine times IV administration (day 30) of indicated dose of EPO-hyFc(H) into cynomolgus monkeys
were evaluated using an ADVIA120 Hematology system. Data, expressed as means 6 SEMs, are obtained from a single experiment. (*p,0.05,
**p,0.01).
doi:10.1371/journal.pone.0024574.g006
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Figure S1 Characterization of EPO-hyFc by Western
blotting. Western blot analyses of r-EPO, darbepoetin alfa, EPO-
hyFc, and EPO-IgG1 Fc using anti-EPO antibody and anti-
human IgG antibodies.
(TIFF)
Figure S2 Histological findings in bone marrow after
the treatment of EPO-hyFc(H) into monkeys. Representa-
tive histologies from the sternum of male cynomolgus monkeys
treated with 1, 3, 10 mg/kg of EPO-hyFc(H) or vehicle control in
a 31-day-toxicity study were shown. Preserved tissues in neutral
buffered 10% formalin were embedded in paraffin, sectioned,
stained with hematoxylin and eosin (H&E), and examined
microscopically (lens magnification 806; Eclipse 801i, Nikkon,
Japan).
(TIFF)
Figure S3 Pharmacodynamic profiles of EPO-hyFc in
BDF-1 mice as a function of sialic acid content. Male
BDF-1 mice (n=8/group) were injected SC with 50, 100, or
200 ng/ml dose of EPO-hyFc(H) (white column) or EPO-hyFc(L)
(black column), and reticulocytes were counted using flow
cytometry. Data, presented as means 6 SEMs, are representative
of two independent experiments. (*p,0.05, **p,0.01).
(TIFF)
Figure S4 Pharmacodynamic profiles of one-third mole
of EPO-hyFc(H) compared to darbepoetin alfa in rats.
Changes in Hb concentrations versus time after the administration
of 135-pmol/kg of darbepoetin alfa (g) or 45 pmol/kg of EPO-
hyFc(H) (N) into SD rats (n=5/group) were evaluated at indicated time
points by automated CBC counter. Changes in Hb concentrations were
expressed relative to the levels in buffer-treated rats after excluding the
level determined prior to administration. Data, presented as means 6
SEMs, are representative of those obtained from two experiments.
(TIFF)
Figure S5 Pharmacodynamic profiles of EPO-hyFc(H)
and darbepoetin alfa in severe anemic rats. The mean Hb
concentrations versus time after the IV administration of
100 pmol/kg of darbepoetin alfa (g) or EPO-hyFc(H) (N) into
severe anemic rats induced by 7 mg/kg cisplatin were evaluated at the
indicated time points using an automated CBC counter. Data, expressed as
means 6 SEMs, are obtained from a single experiment. (*p,0.05
compared with darbepoetin alfa).
(TIFF)
Figure S6 Change of RBC counts and hematocrits after
treatment with EPO-hyFc(H) and darbepoetin alfa in
normal and cisplatin-induced anemic rats. (A, B) The
mean RBC counts and hematocrits versus time after the
administration of darbepoetin alfa (g) or EPO-hyFc(H) (N) into
normal SD rats (n=5/group; 135-pmol/kg) (A) and cisplatin-induced
anemic rats (n=8 (IV) or 6 (SC) /group; 100-pmol/kg) (B) were evaluated
at the indicated time points using an automated CBC counter, respectively.
Data, expressed as means 6 SEMs, are representative of those obtained
from two experiments. (*p,0.05, **p,0.01 compared with darbepoetin
alfa).
(TIFF)
Figure S7 Grand average hydrophobicity of IgD, IgG4,
and hyFc. The hydrophobicities of IgD, IgG4, and hyFc were
determined using ProtScale tool (http://www.exapsy.org/tools).
The red box denotes the partial region of IgD and IgG4 consisting
of hyFc, and the arrow indicates the junction site between IgD and
IgG4 in hyFc. A higher score indicates a greater degree of
hydrophobicity. Black arrow indicates the junction site between
IgD and IgG4.
(TIFF)
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